ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1857

Identifying Core Symptom Domains in the Fibromyalgia Impact Questionnaire: Principal Component Analysis of Data From Milnacipran Clinical Studies

Philip J. Mease1, Robert M. Bennett2, Robert H. Palmer3 and Yong Wang4, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, 3Forest Research Institute, Inc., Jersey City, NJ, 4Forest Research Institute, Jersey City, NJ

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: clinical trials, fibromyalgia, pain and pain management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Fibromyalgia and Soft Tissue Disorders

Session Type: Abstract Submissions (ACR)

Background/Purpose: The Fibromyalgia Impact Questionnaire (FIQ) is a multidimensional instrument that encompasses many of the core domains recommended by OMERACT for evaluation in fibromyalgia (FM) clinical trials, including pain, tenderness, fatigue, global wellbeing, functioning, sleep disturbance, depression, anxiety, and stiffness. In randomized clinical studies, significant decreases in FIQ total scores were found with milnacipran (MLN) vs placebo (PBO), indicating overall improvements in FM severity with this treatment. A Principal Component Analysis (PCA) of data from MLN clinical studies was conducted to determine which FIQ items may be most relevant to FM patients and to further evaluate the effects of MLN on these specific items.

Methods: FIQ data were pooled from 3 double-blind trials in which FM patients were randomized to MLN 100 mg/d (n=1139), MLN 200 mg/d (n=837), or PBO (n=1133). For the PCA analysis, correlations were performed among all FIQ items based on changes from baseline in all patients receiving either MLN or PBO. Principal components with optimally weighted variables were then extracted to identify groups of FIQ items that accounted for most of the variance in FIQ results. Mean changes in FIQ scores were analyzed to evaluate whether items in the extracted components discriminated the effects of MLN treatment in this study population. 

Results: Three independent groups of FIQ items were identified by PCA: Component 1 (“Core Symptoms”) primarily composed of FIQ items 2 (feel good), 4 (do job), 5 (pain), 6 (fatigue), 7 (rest), and 8 (stiffness); Component 2 (“Depression/Anxiety”) primarily composed of FIQ items 9 (anxiety) and 10 (depression); and Component 3 (“Physical Function”) primarily composed of FIQ items 1 (physical impairment) and 3 (work missed). Each FIQ item above represents a meaningful loading with at least a correlation of 0.4 with its component. Component 1 accounted for 37.3% of the total variance in the data, suggesting that this selected set of FIQ items has the strongest relevance in FM patients. Components 2 and 3 accounted for 17.5% and 17.2% of the total variance, respectively, also indicating clinical relevance. Mean changes in FIQ by treatment group indicated significant improvements with MLN (p<.01; both doses vs PBO) for all FIQ items in Components 1 and 2; discrimination of treatment effect was less consistent with the FIQ items in Component 3. 

Conclusion: This PCA analysis of the FIQ resulted in 3 independent components of FM symptom domains. In the population of FM patients included in this analysis, improvements in FIQ scores were largely explained by core FM symptoms, including pain, fatigue, global wellbeing, and stiffness. Independent of these core symptoms, depression/anxiety, and physical functioning also explained a meaningful portion of the FIQ improvement. Additionally, treatment with MLN was associated with improvements in all of the items in these symptom groups.


Disclosure:

P. J. Mease,

Forest Laboratories,

2,

Forest Laboratories,

5,

Forest Laboratories,

8;

R. M. Bennett,

Forest Laboratories,

9;

R. H. Palmer,

Forest Laboratories,

3;

Y. Wang,

Forest Laboratories,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-core-symptom-domains-in-the-fibromyalgia-impact-questionnaire-principal-component-analysis-of-data-from-milnacipran-clinical-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology